Microbiome is the collection of all microbes, such as bacteria, fungi, viruses, and their genes, that naturally live on our bodies and inside us. Although microbes are so small that they require a microscope to see them, they contribute in big ways to human health and wellness. They protect us against pathogens, help our immune system develop, and enable us to digest food to produce energy.
DelveInsight, “Microbiome Competitive landscape, 2022” report provides comprehensive insights about 130+ companies and Microbiome drugs in Microbiome inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To know more about the Microbiome Competitive landscape report, click here: Microbiome Competitive landscape
Key Takeaways from the Microbiome Competitive landscape report:
- Leading Microbiome Companies working in the market are Evelo Biosciences, Vedanta Biosciences, MatriSys Biosystem, 4D Pharma, AOBiome, Caelus Health, DA Volterra, Debiopharm, Enterome Bioscience, Rebiotix, Finch Therapeutics Group, Igen Biotech Group, ImmuneBiotech, Precigen Inc, Immuron, Kaleido Biosciences, YSOPIA Bioscience, MaaT Pharma, Microbiome Therapeutics, MyBiotics, Naked Biome, Nubiyota, OxThera, Pylum Biosciences, Ritter Pharmaceuticals, Seres Therapeutics, Symberix and Others.
- Key Microbiome therapies in various stages of development include RBX 2660, DAV 132, B244, EDP1815, Blautix, MRx518, MSB- 01, VE-202, ABI M201, AZT-04, MaaT 033, MSB 3163 and Others.
- In May 2022, Gnubiotics Sciences SA, announced a strategic partnership agreement with ADM,a global leader in human and animal nutrition.The strategic partnership is centered on the commercialization of innovative microbiome solutions for companion animal health and wellbeing.
DelveInsight’s Microbiome Report covers around 200+ products under different phases of clinical development like
- Assessment by Microbiome Product Type
- Assessment by Stage and Product Type of Microbiome
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration of Microbiome
- Assessment by Microbiome Molecule Type
- Assessment by Stage and Molecule Type of Microbiome
Emerging Microbiome Drugs Under Different Phases of Clinical Development Include:
Some of the Microbiome therapies are B244, VE202 and Many Others.
Further Microbiome product details are provided in the report. Download the Microbiome Pipeline report to learn more about the emerging Microbiome therapies at: Microbiome Therapeutics
Key companies in the Microbiome Therapeutics Market:
Some of the Microbiome Companies working in the market are Evelo Biosciences, Vedanta Biosciences, MatriSys Biosystem, 4D Pharma, AOBiome, Caelus Health, DA Volterra, Debiopharm, Enterome Bioscience, Rebiotix, Finch Therapeutics Group, Igen Biotech Group, ImmuneBiotech, Precigen Inc, Immuron, Kaleido Biosciences, YSOPIA Bioscience, MaaT Pharma, Microbiome Therapeutics, MyBiotics, Naked Biome, Nubiyota, OxThera, Pylum Biosciences, Ritter Pharmaceuticals, Seres Therapeutics, Symberix and Others.
Request for Sample PDF Report to know in detail about the recent developments and advancements in Microbiome clinical trials– Phases of Microbiome Drugs in pipeline
Table of Content (TOC)
1. Microbiome Pipeline Report Introduction
2. Microbiome Pipeline Report Executive Summary
3. Microbiome Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Microbiome Clinical Trial Therapeutics
6. Microbiome Pipeline: Late Stage Products (Pre-registration)
7. Microbiome Pipeline: Late Stage Products (Phase III)
8. Microbiome Pipeline: Mid Stage Products (Phase II)
9. Microbiome Pipeline: Early Stage Products (Phase I)
10. Microbiome Pipeline Therapeutic Assessment
11. Inactive Products in the Microbiome Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Microbiome Companies
14. Key Products in the Microbiome Pipeline
15. Unmet Needs
16. Microbiome Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Download Sample PDF Report to know more about @ Microbiome drugs
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end- to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/microbiome-competitive-landscape